A Phase 2 interventional study of Ruxolitinib 1.5% cream and NB-UVB phototherapy in Vitiligo, sponsored by Incyte Corporation. Completed at 13 sites in 2 countries. Open to participants aged 12 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-02-20.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.
Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 9th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 2, and was the 7th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in Argentina, Austria, Belgium and 11 more countries
Ages 6–11
Incyte Corporation · Sites in United States, Canada
Ages 2–11
Hospital Authority, Hong Kong · Sites in Hong Kong
Ages 18–85
Kafrelsheikh University · Sites in Egypt
Ages 12+
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 2–11
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 12 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2016; this study’s year is marked. 1 started in 2022.
This study's enrollment of 55 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 90 across the 14 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 14 have an industry lead sponsor. The 6 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
12 studies in Vitiligo by Incyte Corporation: 2 open now, 4 under way, 4 of them phase 3. Of 8 finished, 8 (100%) have results posted.
Among the 12 studies in Vitiligo by Incyte Corporation, this one is the 11th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 2, and was the 7th registered.
Incyte Corporation’s Vitiligo studies by the year they started, since 2017.
2 of the studies testing ruxolitinib in Vitiligo that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06804811Phase 3Incyte CorporationA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | 2027-04-30 |
| NCT07909668Kafrelsheikh UniversityTopical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ruxolitinib in Vitiligo, from their registry updates:
Among Incyte Corporation’s 12 in Vitiligo:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A clinical diagnosis of nonsegmental vitiligo with depigmented area including all of the following:
Exclusion Criteria:
Participants will initially apply ruxolitinib 1.5%mg cream as a monotherapy. At week 12, those who have \< 25% improvement in total body Vitiligo Area Scoring Index (T-VASI25) will have NB-UVB phototherapy added to their ruxolitinib 1.5% cream BID regimen. NB-UVB will be given 3 times per week starting at Week 12 through Week 48 (36 weeks). For participants who receive combination therapy, NB-UVB machines will be supplied by the sponsor for at home use during the study.
Drug: Ruxolitinib 1.5% cream · Device: NB-UVB phototherapy
Participants will apply ruxolitinib 1.5% cream BID as monotherapy. Participants who have ≥ T-VASI25 at Week 12 will continue on ruxolitinib 1.5% cream BID alone.
Drug: Ruxolitinib 1.5% cream
Ruxolitinib cream 1.5% applied twice a day (BID).
NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit
Also known as: Narrow-Band Ultraviolet B Phototherapy
Change From Baseline in Total Body Vitiligo Area Scoring Index (T-VASI) at Week 48
T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of body surface area \[BSA\] estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: Baseline; Week 48
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
Time frame: up to approximately 52 weeks
Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Each Post-Baseline Visit
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: Baseline; up to Week 48
Percentage of Participants Achieving a ≥75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Each Post-Baseline Visit
An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: Baseline; up to Week 48
Percentage of Participants Achieving a ≥90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Each Post-Baseline Visit
An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: Baseline; up to Week 48
Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Each Post-Baseline Visit
A T-VASI50 responder achieved ≥50% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: Baseline; up to Week 48
Percentage of Participants Achieving a ≥75% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI75) Score at Each Post-Baseline Visit
A T-VASI75 responder achieved ≥75% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: Baseline; up to Week 48
Percentage of Participants Achieving a ≥90% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI90) Score at Each Post-Baseline Visit
A T-VASI90 responder achieved ≥90% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: Baseline; up to Week 48
Change From Baseline in F-VASI at Each Post-Baseline Visit
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; up to Week 48
Percentage Change From Baseline in F-VASI at Each Post-Baseline Visit
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
Time frame: Baseline; up to Week 48
Change From Baseline in T-VASI at Each Post-Baseline Visit
T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from BL was calculated as the post-BL value minus the BL value.
Time frame: Baseline; up to Week 48
Percentage Change From Baseline in T-VASI at Each Post-Baseline Visit
T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Time frame: Baseline; up to Week 48
Change From Baseline in Facial Body Surface Area (F-BSA) at Each Post-Baseline Visit
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; up to Week 48
Percentage Change From Baseline in F-BSA at Each Post-Baseline Visit
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
Time frame: Baseline; up to Week 48
Change From Baseline in Total Body Surface Area (T-BSA) at Each Post-Baseline Visit
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; up to Week 48
Percentage Change From Baseline in T-BSA at Each Post-Baseline Visit
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Time frame: Baseline; up to Week 48
Plasma Concentration of Ruxolitinib at Weeks 4, 12, and 16
The concentration of ruxolitinib in the plasma was assessed.
Time frame: pre-application at Weeks 4, 12, and 16
| Milestone | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Started | 20 | 35 |
| Completed | 6 | 26 |
| Not completed | 14 | 9 |
| Withdrew: Lost to follow-up | 5 | 1 |
| Withdrew: Withdrawal by subject | 6 | 7 |
| Withdrew: Withdrawn by sponsor: noncompliance | 0 | 1 |
| Withdrew: Left country | 1 | 0 |
| Withdrew: Noncompliance with investigational product | 1 | 0 |
| Withdrew: Withdrawn by sponsor: surgery to remove excess skin | 1 | 0 |
T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of body surface area \[BSA\] estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).
| scores on a scale | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Baseline | 6.58 ± 2.163 | 6.87 ± 2.103 |
| Change from Baseline at Week 48 | -3.43 ± 1.219 | -3.46 ± 2.106 |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
| Participants | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 9 | 21 |
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Week 4 | 6.3 (0.2 to 30.2) | 5.7 (0.7 to 19.2) |
| Week 8 | 21.4 (4.7 to 50.8) | 17.1 (6.6 to 33.6) |
| Week 12 | 63.6 (30.8 to 89.1) | 31.4 (16.9 to 49.3) |
| Week 16 | 85.7 (42.1 to 99.6) | 45.7 (28.8 to 63.4) |
| Week 24 | 100.0 (59.0 to 100.0) | 76.5 (58.8 to 89.3) |
| Week 32 | 100.0 (54.1 to 100.0) | 87.5 (71.0 to 96.5) |
| Week 40 | 100.0 (54.1 to 100.0) | 92.9 (76.5 to 99.1) |
| Week 48 | 100.0 (54.1 to 100.0) | 96.2 (80.4 to 99.9) |
An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Week 4 | 6.3 (0.2 to 30.2) | 0.0 (0.0 to 10.0) |
| Week 8 | 7.1 (0.2 to 33.9) | 0.0 (0.0 to 10.0) |
| Week 12 | 45.5 (16.7 to 76.6) | 14.3 (4.8 to 30.3) |
| Week 16 | 57.1 (18.4 to 90.1) | 20.0 (8.4 to 36.9) |
| Week 24 | 85.7 (42.1 to 99.6) | 47.1 (29.8 to 64.9) |
| Week 32 | 83.3 (35.9 to 99.6) | 59.4 (40.6 to 76.3) |
| Week 40 | 100.0 (54.1 to 100.0) | 71.4 (51.3 to 86.8) |
| Week 48 | 100.0 (54.1 to 100.0) | 84.6 (65.1 to 95.6) |
An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Week 4 | 0.0 (0.0 to 20.6) | 0.0 (0.0 to 10.0) |
| Week 8 | 0.0 (0.0 to 23.2) | 0.0 (0.0 to 10.0) |
| Week 12 | 9.1 (0.2 to 41.3) | 0.0 (0.0 to 10.0) |
| Week 16 | 42.9 (9.9 to 81.6) | 2.9 (0.1 to 14.9) |
| Week 24 | 42.9 (9.9 to 81.6) | 17.6 (6.8 to 34.5) |
| Week 32 | 50.0 (11.8 to 88.2) | 34.4 (18.6 to 53.2) |
| Week 40 | 50.0 (11.8 to 88.2) | 53.6 (33.9 to 72.5) |
| Week 48 | 66.7 (22.3 to 95.7) | 53.8 (33.4 to 73.4) |
A T-VASI50 responder achieved ≥50% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).
| percentage of participants | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Week 4 | 0.0 (0.0 to 20.6) | 0.0 (0.0 to 10.0) |
| Week 8 | 0.0 (0.0 to 23.2) | 0.0 (0.0 to 10.0) |
| Week 12 | 18.2 (2.3 to 51.8) | 0.0 (0.0 to 10.0) |
| Week 16 | 42.9 (9.9 to 81.6) | 2.9 (0.1 to 14.9) |
| Week 24 | 71.4 (29.0 to 96.3) | 23.5 (10.7 to 41.2) |
| Week 32 | 66.7 (22.3 to 95.7) | 34.4 (18.6 to 53.2) |
| Week 40 | 83.3 (35.9 to 99.6) | 46.4 (27.5 to 66.1) |
| Week 48 | 83.3 (35.9 to 99.6) | 57.7 (36.9 to 76.6) |
A T-VASI75 responder achieved ≥75% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).
| percentage of participants | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Week 4 | 0.0 (0.0 to 20.6) | 0.0 (0.0 to 10.0) |
| Week 8 | 0.0 (0.0 to 23.2) | 0.0 (0.0 to 10.0) |
| Week 12 | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 10.0) |
| Week 16 | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 10.0) |
| Week 24 | 28.6 (3.7 to 71.0) | 5.9 (0.7 to 19.7) |
| Week 32 | 50.0 (11.8 to 88.2) | 6.3 (0.8 to 20.8) |
| Week 40 | 50.0 (11.8 to 88.2) | 7.1 (0.9 to 23.5) |
| Week 48 | 50.0 (11.8 to 88.2) | 19.2 (6.6 to 39.4) |
A T-VASI90 responder achieved ≥90% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).
| percentage of participants | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Week 4 | 0.0 (0.0 to 20.6) | 0.0 (0.0 to 10.0) |
| Week 8 | 0.0 (0.0 to 23.2) | 0.0 (0.0 to 10.0) |
| Week 12 | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 10.0) |
| Week 16 | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 10.0) |
| Week 24 | 14.3 (0.4 to 57.9) | 2.9 (0.1 to 15.3) |
| Week 32 | 16.7 (0.4 to 64.1) | 3.1 (0.1 to 16.2) |
| Week 40 | 16.7 (0.4 to 64.1) | 7.1 (0.9 to 23.5) |
| Week 48 | 16.7 (0.4 to 64.1) | 7.7 (0.9 to 25.1) |
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| scores on a scale | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Baseline | 1.00 ± 0.446 | 0.91 ± 0.522 |
| Week 4 | -0.13 ± 0.234 | -0.05 ± 0.114 |
| Week 8 | -0.26 ± 0.302 | -0.14 ± 0.204 |
| Week 12 | -0.51 ± 0.382 | -0.32 ± 0.330 |
| Week 16 | -0.68 ± 0.319 | -0.41 ± 0.428 |
| Week 24 | -0.83 ± 0.276 | -0.60 ± 0.536 |
| Week 32 | -0.87 ± 0.311 | -0.70 ± 0.514 |
| Week 40 | -0.88 ± 0.326 | -0.79 ± 0.582 |
| Week 48 | -0.88 ± 0.322 | -0.82 ± 0.603 |
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
| percent change | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Week 4 | -11.69 ± 20.612 | -6.24 ± 12.472 |
| Week 8 | -25.57 ± 24.957 | -14.62 ± 20.210 |
| Week 12 | -54.62 ± 34.297 | -32.43 ± 26.031 |
| Week 16 | -73.31 ± 27.030 | -40.64 ± 27.945 |
| Week 24 | -87.02 ± 12.247 | -61.31 ± 28.613 |
| Week 32 | -89.37 ± 11.661 | -72.69 ± 24.815 |
| Week 40 | -90.44 ± 11.006 | -80.70 ± 20.478 |
| Week 48 | -90.73 ± 11.002 | -85.55 ± 15.856 |
T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from BL was calculated as the post-BL value minus the BL value.
| scores on a scale | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Baseline | 6.58 ± 2.163 | 6.87 ± 2.103 |
| Week 4 | -0.40 ± 0.711 | -0.06 ± 0.179 |
| Week 8 | -0.85 ± 0.865 | -0.17 ± 0.480 |
| Week 12 | -1.61 ± 1.320 | -0.52 ± 0.710 |
| Week 16 | -2.47 ± 1.532 | -0.94 ± 0.949 |
| Week 24 | -3.21 ± 1.686 | -1.73 ± 1.679 |
| Week 32 | -3.03 ± 1.542 | -2.34 ± 1.746 |
| Week 40 | -3.42 ± 1.235 | -2.97 ± 1.867 |
| Week 48 | -3.43 ± 1.219 | -3.46 ± 2.106 |
T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
| percent change | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Week 4 | -6.12 ± 11.217 | -1.02 ± 3.063 |
| Week 8 | -15.21 ± 15.360 | -2.79 ± 6.833 |
| Week 12 | -29.76 ± 24.512 | -7.88 ± 9.796 |
| Week 16 | -42.28 ± 23.530 | -14.82 ± 15.536 |
| Week 24 | -57.31 ± 26.271 | -27.54 ± 26.386 |
| Week 32 | -61.19 ± 28.399 | -35.51 ± 27.266 |
| Week 40 | -69.63 ± 19.748 | -43.76 ± 27.441 |
| Week 48 | -69.76 ± 18.519 | -50.39 ± 28.689 |
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| percentage of facial surface area | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Baseline | 1.12 ± 0.524 | 0.96 ± 0.615 |
| Week 4 | -0.04 ± 0.126 | -0.02 ± 0.088 |
| Week 8 | -0.08 ± 0.148 | -0.06 ± 0.194 |
| Week 12 | -0.25 ± 0.246 | -0.17 ± 0.299 |
| Week 16 | -0.40 ± 0.283 | -0.22 ± 0.378 |
| Week 24 | -0.63 ± 0.150 | -0.34 ± 0.426 |
| Week 32 | -0.70 ± 0.167 | -0.44 ± 0.457 |
| Week 40 | -0.75 ± 0.207 | -0.58 ± 0.577 |
| Week 48 | -0.77 ± 0.234 | -0.67 ± 0.716 |
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
| percent change | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Week 4 | -4.02 ± 12.769 | -1.50 ± 4.345 |
| Week 8 | -7.25 ± 13.838 | -4.37 ± 12.349 |
| Week 12 | -24.12 ± 22.508 | -14.83 ± 19.575 |
| Week 16 | -39.37 ± 35.289 | -19.34 ± 23.332 |
| Week 24 | -65.36 ± 25.090 | -34.37 ± 30.969 |
| Week 32 | -72.67 ± 20.378 | -45.42 ± 31.086 |
| Week 40 | -77.02 ± 20.748 | -56.25 ± 31.498 |
| Week 48 | -78.06 ± 20.018 | -60.51 ± 29.172 |
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| percentage of total body surface area | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Baseline | 7.00 ± 2.301 | 7.22 ± 2.118 |
| Week 4 | -0.19 ± 0.701 | -0.02 ± 0.200 |
| Week 8 | -0.48 ± 0.794 | -0.01 ± 0.430 |
| Week 12 | -0.96 ± 0.952 | -0.17 ± 0.544 |
| Week 16 | -1.43 ± 1.359 | -0.34 ± 0.659 |
| Week 24 | -2.14 ± 1.462 | -0.80 ± 1.538 |
| Week 32 | -2.13 ± 1.556 | -1.12 ± 1.689 |
| Week 40 | -2.33 ± 1.617 | -1.50 ± 1.988 |
| Week 48 | -2.37 ± 1.627 | -1.93 ± 2.312 |
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
| percent change | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Week 4 | -2.65 ± 10.057 | -0.36 ± 3.374 |
| Week 8 | -7.71 ± 13.609 | -0.24 ± 6.006 |
| Week 12 | -16.92 ± 17.590 | -2.60 ± 7.586 |
| Week 16 | -23.09 ± 22.344 | -5.45 ± 9.946 |
| Week 24 | -38.02 ± 23.485 | -12.50 ± 21.869 |
| Week 32 | -42.86 ± 28.257 | -16.91 ± 23.758 |
| Week 40 | -46.61 ± 29.639 | -21.92 ± 27.234 |
| Week 48 | -47.03 ± 29.370 | -27.30 ± 30.712 |
The concentration of ruxolitinib in the plasma was assessed.
| nanomolar | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB |
|---|---|---|
| Week 4 | 18.7 ± 19.0 | 51.1 ± 45.4 |
| Week 12 | 23.3 ± 23.1 | 53.7 ± 55.0 |
| Week 16 | 49.3 ± 38.8 | 55.4 ± 43.9 |
Collected over up to approximately 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib 1.5% Cream BID | 0/20 (0%) | 2/20 (10%) | 9/20 (45%) |
| Ruxolitinib 1.5% Cream BID + NB-UVB | 0/35 (0%) | 0/35 (0%) | 15/35 (42.9%) |
| Total | 0/55 (0%) | 2/55 (3.6%) | 24/55 (43.6%) |
| Event | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB | Total |
|---|---|---|---|
| Generalised tonic-clonic seizureNervous system disorders | 1/20 | 0/35 | 1/55 |
| Intestinal obstructionGastrointestinal disorders | 1/20 | 0/35 | 1/55 |
| Small intestinal perforationGastrointestinal disorders | 1/20 | 0/35 | 1/55 |
| Event | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB | Total |
|---|---|---|---|
| Application site acneGeneral disorders | 2/20 | 4/35 | 6/55 |
| Procedural site reactionInjury, poisoning and procedural complications | 0/20 | 4/35 | 4/55 |
| BronchitisInfections and infestations | 2/20 | 0/35 | 2/55 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/20 | 1/35 | 3/55 |
| PyrexiaGeneral disorders | 2/20 | 0/35 | 2/55 |
| Oral herpesInfections and infestations | 0/20 | 3/35 | 3/55 |
| Upper respiratory tract infectionInfections and infestations | 1/20 | 3/35 | 4/55 |
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 0/20 | 2/35 | 2/55 |
| AcneSkin and subcutaneous tissue disorders | 1/20 | 1/35 | 2/55 |
| Animal biteInjury, poisoning and procedural complications | 1/20 | 0/35 | 1/55 |
| Age, Continuous(years) | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB | Total |
|---|---|---|---|
| Mean | 42.0 ± 18.97 | 52.5 ± 14.25 | 48.7 ± 16.75 |
| Sex: Female, Male(Participants) | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB | Total |
|---|---|---|---|
| Female | 10 | 17 | 27 |
| Male | 10 | 18 | 28 |
| Ethnicity (NIH/OMB)(Participants) | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 18 | 32 | 50 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib 1.5% Cream BID | Ruxolitinib 1.5% Cream BID + NB-UVB | Total |
|---|---|---|---|
| White/Caucasian | 11 | 25 | 36 |
| Black/African-American | 1 | 2 | 3 |
| Asian | 6 | 6 | 12 |
| American-Indian/Alaska Native | 2 | 0 | 2 |
| East Indian | 0 | 1 | 1 |
| Arab | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from May 2022 to primary completion in Dec 2023, 19 months.
Results were first posted in Feb 2025, 1 year 2 months after primary completion.
Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's 19 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib